AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
6 undervalued US shares that crushed earnings
Atlassian and CarMax remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued REIT offers attractive yield post earnings
Resilient income, attractive yield for Aussie REIT.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 5.60 | 0.06% |
| CAC 40 | 8,539.31 | 40.29 | -0.47% |
| DAX 40 | 26,252.97 | 85.64 | -0.33% |
| Dow JONES (US) | 53,459.78 | 272.63 | -0.51% |
| FTSE 100 | 10,722.46 | 2.16 | 0.02% |
| HKSE | 25,471.15 | 17.92 | 0.07% |
| NASDAQ | 26,644.91 | 84.25 | -0.32% |
| Nikkei 225 | 67,460.73 | 1,759.52 | -2.54% |
| NZX 50 Index | 13,866.18 | 144.20 | 1.05% |
| S&P 500 | 7,745.06 | 40.70 | -0.52% |
| S&P/ASX 200 | 9,070.00 | 5.20 | 0.06% |
| SSE Composite Index | 3,990.30 | 7.65 | 0.19% |